ECSP045433A - "uso de docetaxel/doxorrubicina/ciclofosfamida en la terapia adyuvante de cancer de mama y ovario" - Google Patents

"uso de docetaxel/doxorrubicina/ciclofosfamida en la terapia adyuvante de cancer de mama y ovario"

Info

Publication number
ECSP045433A
ECSP045433A EC2004005433A ECSP045433A ECSP045433A EC SP045433 A ECSP045433 A EC SP045433A EC 2004005433 A EC2004005433 A EC 2004005433A EC SP045433 A ECSP045433 A EC SP045433A EC SP045433 A ECSP045433 A EC SP045433A
Authority
EC
Ecuador
Prior art keywords
docetaxel
cyclophosphamide
breast
cancer
doxorrubicin
Prior art date
Application number
EC2004005433A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of ECSP045433A publication Critical patent/ECSP045433A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a un nuevo método de terapia adyuvante en el tratamiento de cáncer de mama u ovario metastático, que comprende administrar seis ciclos de docetaxel, doxorrubicina y ciclofosfamida a una paciente que lo necesita, en el que dichas dosis tienen un efecto terapéutico marcado cuando se compara con otras terapias adyuvantes.
EC2004005433A 2002-05-17 2004-11-16 "uso de docetaxel/doxorrubicina/ciclofosfamida en la terapia adyuvante de cancer de mama y ovario" ECSP045433A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38085002P 2002-05-17 2002-05-17

Publications (1)

Publication Number Publication Date
ECSP045433A true ECSP045433A (es) 2005-01-03

Family

ID=29550025

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005433A ECSP045433A (es) 2002-05-17 2004-11-16 "uso de docetaxel/doxorrubicina/ciclofosfamida en la terapia adyuvante de cancer de mama y ovario"

Country Status (28)

Country Link
US (2) US20040014694A1 (es)
EP (1) EP1507573A1 (es)
JP (1) JP4773719B2 (es)
KR (1) KR20050000544A (es)
CN (1) CN1652845A (es)
AU (1) AU2003244646B2 (es)
BR (1) BR0310026A (es)
CA (1) CA2486124A1 (es)
CR (1) CR7575A (es)
EC (1) ECSP045433A (es)
HR (1) HRPK20041072B3 (es)
IL (1) IL165214A0 (es)
MA (1) MA27417A1 (es)
ME (2) ME00055B (es)
MX (1) MXPA04010640A (es)
MY (1) MY146533A (es)
NO (1) NO20045370L (es)
NZ (1) NZ535992A (es)
OA (1) OA12819A (es)
PA (1) PA8574001A1 (es)
RS (1) RS96304A (es)
RU (1) RU2321396C2 (es)
TN (1) TNSN04217A1 (es)
TW (1) TWI374741B (es)
UA (1) UA81628C2 (es)
UY (1) UY27812A1 (es)
WO (1) WO2003097164A1 (es)
ZA (1) ZA200408549B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2540108A1 (en) * 2003-09-25 2005-04-07 Astellas Pharma Inc. Antitumor agent_comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
RU2265440C2 (ru) * 2004-01-13 2005-12-10 Ростовский научно-исследовательский онкологический институт МЗ РФ Способ предоперационного лечения рака молочной железы
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
US7776832B2 (en) * 2006-04-21 2010-08-17 Gem Pharmaceuticals, Llc Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines
US20080085879A1 (en) * 2006-08-31 2008-04-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods of treating estrogen-responsive conditions by orphan nuclear receptor activation
WO2012131399A1 (en) * 2011-04-01 2012-10-04 Astrazeneca Ab Therapeutic treatment
PT4241849T (pt) 2011-10-14 2024-10-30 Hoffmann La Roche Utilizações do inibidor da dimerização de her2 pertuzumab e artigo de fabrico que inclui o mesmo
PT2785349T (pt) 2011-11-30 2019-12-11 Astrazeneca Ab Tratamento combinado de cancro
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
WO2014169067A1 (en) * 2013-04-09 2014-10-16 Merrimack Pharmaceuticals, Inc. Compositions for improving outcomes of liposomal chemotherapy
CN106163558A (zh) * 2014-04-25 2016-11-23 豪夫迈·罗氏有限公司 用曲妥珠单抗‑mcc‑dm1和帕妥珠单抗治疗早期乳腺癌的方法
WO2016005962A2 (en) 2014-07-11 2016-01-14 Dr. Reddy’S Laboratories Limited Stable liquid formulations of cyclophosphamide and processes
US10849916B2 (en) 2014-07-11 2020-12-01 Dr. Reddys Laboratories Limited Stable liquid formulations of cyclophosphamide and its impurities
SG10202008673WA (en) 2015-03-06 2020-10-29 Beyondspring Pharmaceuticals Inc Method of treating cancer associated with a ras mutation
US10155748B2 (en) 2015-07-13 2018-12-18 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
US20190054019A1 (en) * 2015-10-22 2019-02-21 Universidade De Santiago De Compostela Methods for using regulators for increasing the expression or activation of p53 and/or regulators for reducing or inhibiting the expression of p63-alpha, for the treatment of non-alcoholic fatty liver disease (nafld) and/or non-alcoholic steatohepatitis (nash)
JP2019511565A (ja) 2016-02-08 2019-04-25 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド ツカレゾールまたはそのアナログを含む組成物
AU2017278245B2 (en) 2016-06-06 2022-09-15 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing neutropenia
WO2018039452A1 (en) * 2016-08-24 2018-03-01 The Wistar Institute Of Anatomy And Biology Methods of treating cancers with chemotherapy with reduced toxicity
US11491147B2 (en) * 2016-10-03 2022-11-08 Indiana University Research And Technology Corporation Combination drug therapy reduces PARP-1 related DNA repair and increases the efficacy of genotoxic agents
EP3565812B1 (en) 2017-01-06 2023-12-27 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
KR20240110997A (ko) 2017-02-01 2024-07-16 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증의 감소 방법
US11077189B2 (en) 2017-03-02 2021-08-03 Genentech Inc. Adjuvant treatment of HER2-positive breast cancer
EP3743074A4 (en) 2018-01-24 2021-12-15 Beyondspring Pharmaceuticals Inc. COMPOSITION AND METHOD FOR REDUCING THROMBOCYTOPENIA BY THE ADMINISTRATION OF PLINABULINE
JP7373170B2 (ja) * 2018-06-22 2023-11-02 オハイオ ステート イノベーション ファウンデーション ジヒドロオロト酸デヒドロゲナーゼ阻害のための方法及び組成物
WO2022216908A1 (en) 2021-04-09 2022-10-13 Beyondspring Pharmaceuticals, Inc. Therapeutic compositions and methods for treating tumors
CN115969792A (zh) * 2023-01-29 2023-04-18 常州金远药业制造有限公司 一种紫杉烷类药物与环磷酰胺共载载药脂质体制备方法
CN116870019A (zh) * 2023-02-03 2023-10-13 大连理工大学 一种具有协同增效作用的药物组合物及其在癌症化疗中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
MX9102128A (es) 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US6441026B1 (en) * 1993-11-08 2002-08-27 Aventis Pharma S.A. Antitumor compositions containing taxane derivatives
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
US6262054B1 (en) * 1996-02-01 2001-07-17 Sloan-Kettering Institute Of Cancer Research Combination therapy method for treating breast cancer using edatrexate
US6323205B1 (en) * 1996-07-17 2001-11-27 Sloan-Kettering Institute For Cancer Research Combinations of 10-propargyl-10-deazaaminopterin and taxols and methods of using same in the treatment of tumors
US6541508B2 (en) * 1999-09-13 2003-04-01 Nobex Corporation Taxane prodrugs
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
US20020128228A1 (en) * 2000-12-01 2002-09-12 Wen-Jen Hwu Compositions and methods for the treatment of cancer

Also Published As

Publication number Publication date
NZ535992A (en) 2008-11-28
HRP20041072A2 (en) 2005-06-30
OA12819A (en) 2006-07-10
UY27812A1 (es) 2003-11-28
JP2005529925A (ja) 2005-10-06
NO20045370L (no) 2004-12-08
US20040014694A1 (en) 2004-01-22
KR20050000544A (ko) 2005-01-05
PA8574001A1 (es) 2003-12-19
AU2003244646B2 (en) 2008-08-07
ME00055B (me) 2010-10-10
WO2003097164A1 (en) 2003-11-27
RU2004136984A (ru) 2005-06-27
IL165214A0 (en) 2005-12-18
TW200407152A (en) 2004-05-16
TNSN04217A1 (en) 2007-03-12
TWI374741B (en) 2012-10-21
CR7575A (es) 2006-05-10
MA27417A1 (fr) 2005-07-01
AU2003244646A1 (en) 2003-12-02
US20070265213A1 (en) 2007-11-15
CA2486124A1 (en) 2003-11-27
RS96304A (sr) 2006-10-27
UA81628C2 (uk) 2008-01-25
HRPK20041072B3 (hr) 2007-07-31
MXPA04010640A (es) 2005-08-16
ZA200408549B (en) 2006-01-25
RU2321396C2 (ru) 2008-04-10
MY146533A (en) 2012-08-15
CN1652845A (zh) 2005-08-10
EP1507573A1 (en) 2005-02-23
BR0310026A (pt) 2005-02-15
MEP16308A (en) 2010-06-10
JP4773719B2 (ja) 2011-09-14

Similar Documents

Publication Publication Date Title
CR7575A (es) Uso de docetaxel/doxorrubicina/ciclofosfamida en la terapia adyuvante de cancer de mama y ovario
MXPA03010121A (es) Terapia de combinacion que utiliza anticuerpos anti-receptor de factor de crecimiento epidermico y agentes anti-hormonales.
ATE472551T1 (de) Tocopherolmodifizierte therapeutische arzneimittelverbindung
WO2004062604A3 (en) Treatment of cancer with 2-deoxyglucose
DE60023476D1 (de) Kombination von doctaxel und rhumab her2 zür krebsbehandlung
NO20032027L (no) Effektive antitumorbehandlinger
NO20072543L (no) Anti-cancer-behandling
BRPI0508700A (pt) uso de sns-595, composição farmacêutica, e, pó liofilizado
EA200700686A1 (ru) Липосомы, включающие радиоактивный изотоп, и цитотоксический агент для комбинированной терапии
MX2009003532A (es) Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
WO2000040229A3 (en) Synergistic tumorcidal response induced by histamine
MXPA04001912A (es) Aminobenzofenonas novedosas.
DE60019947D1 (de) Vorbeugung von kolorektalkrebs
MXPA05009849A (es) Terapia combinada que comprende nemorubicina y un inhibidor de la ciclooxigenasa-2.
AR047154A1 (es) Tratamiento del insomnio en pacientes humanos administrandoles una cantidad diaria de gaboxadol
AU2002319223A1 (en) Medicament for treating tumours and their metastases using a binding molecule against bone-sialoprotein
TH102680A (th) การใช้โดซีแทกเซล/ดอกโซรูบิซิน/ไซโคลฟอสฟาไมด์ ในการรักษาแบบเสริม
BRPI0409870A (pt) uso de irinotecano para tratamento de cáncer de mama resistente
BR0307979A (pt) Método e preparação farmacêutica para reduzir as toxicidades gastrointestinais induzidas por terapia citoablatica , e método para melhorar terapia citoablativa de câncer
ATE378089T1 (de) Präoperative behandlung von brustkrebs
DE60233869D1 (de) Prävention von epithelzellkarzinom
MY128724A (en) Liver selective theraphy.